Immunome, Inc. (IMNM) vs Zai Lab Limited Unsponsored ADR (ZLAB)

Immunome, Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Zai Lab Limited Unsponsored ADR is the larger, with a market value of $2.9B against $2.6B — 1.1× the size. Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against 5.10%. Immunome, Inc. has the higher net margin (0.00% vs −41.9%) and the lower return on invested capital (−3,323.0% vs −129.3%). Across the 17 metrics below, Immunome, Inc. leads on 9 and Zai Lab Limited Unsponsored ADR on 8.

Valuation

Metric IMNM ZLAB Biotechnology median
P/E n/m n/m 7.88
P/S 190.93 6.21 11.47
P/B 4.58 4.60 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 149.65 5.14 10.73
Earnings yield (11.92%) (6.85%) (28.84%)
Free cash flow yield (9.11%) (5.82%) (23.03%)

Profitability

Metric IMNM ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin 0.00% (58.74%) 0.00%
Net margin 0.00% (41.86%) 0.00%
Free cash flow margin 0.00% (36.13%) 0.00%
Return on equity (64.03%) (26.91%) (57.72%)
Return on assets (59.03%) (16.81%) (49.22%)
Return on invested capital (3,322.99%) (129.34%) 0.00%

Growth

Metric IMNM ZLAB Biotechnology median
Revenue growth (TTM) 16.74% 5.10% 5.64%
EPS growth (last fiscal year) 51.40% 38.46% —
Revenue growth, 5-year CAGR — 56.54% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMNM ZLAB Biotechnology median
Debt to equity 0.00 0.39 0.00
Current ratio 15.08 2.13 4.73
Net debt to EBITDA 2.92 2.66 0.96

Dividend

Metric IMNM ZLAB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMNM ZLAB Biotechnology median
Market cap 2.56b 2.85b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack